GlaxoSmithKline Stock Performance

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

GlaxoSmithKline PLC has performance score of 7 on a scale of 0 to 100. The company retains a Market Volatility (i.e. Beta) of -0.1845, which attests that not very significant volatility relative to the market. Let's try to break down what GlaxoSmithKline's beta means in this case. As returns on the market increase, returns on owning GlaxoSmithKline PLC are expected to decrease at a much lower rate. During the bear market, GlaxoSmithKline PLC is likely to outperform the market. Although it is extremely important to respect GlaxoSmithKline PLC current price history, it is better to be realistic regarding the information on equity current price movements. The philosophy in determining future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By evaluating GlaxoSmithKline PLC technical indicators you can presently evaluate if the expected return of 0.17% will be sustainable into the future. GlaxoSmithKline PLC right now retains a risk of 1.57%. Please check out GlaxoSmithKline PLC coefficient of variation, semi variance, price action indicator, as well as the relationship between the treynor ratio and daily balance of power to decide if GlaxoSmithKline PLC will be following its current trending patterns.

Search Stock Performance


GlaxoSmithKline PLC Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in GlaxoSmithKline PLC are ranked lower than 7 (%) of all global equities and portfolios over the last 30 days. Regardless of fairly weak technical and fundamental indicators, GlaxoSmithKline PLC may actually be approaching a critical reversion point that can send shares even higher in August 2020.
Quick Ratio0.54
Fifty Two Week Low31.43
Target High Price51.00
Fifty Two Week High48.25
Payout Ratio74.09%
Trailing Annual Dividend Yield2.57%
Target Low Price42.10

GlaxoSmithKline PLC Relative Risk vs. Return Landscape

If you would invest  3,714  in GlaxoSmithKline PLC on June 2, 2020 and sell it today you would earn a total of  391.00  from holding GlaxoSmithKline PLC or generate 10.53% return on investment over 30 days. GlaxoSmithKline PLC is generating 0.1712% of daily returns assuming volatility of 1.5687% on return distribution over 30 days investment horizon. In other words, 13% of equities are less volatile than the company and above 97% of equities are expected to generate higher returns over the next 30 days.
 Daily Expected Return (%) 
      Risk (%) 
Considering the 30-days investment horizon, GlaxoSmithKline PLC is expected to generate 2.15 times less return on investment than the market. But when comparing it to its historical volatility, the company is 1.33 times less risky than the market. It trades about 0.11 of its potential returns per unit of risk. The DOW is currently generating roughly 0.18 of returns per unit of risk over similar time horizon.

GlaxoSmithKline PLC Market Risk Analysis

Sharpe Ratio = 0.1091
Good Returns
Average Returns
Small ReturnsGSK
Negative Returns

GlaxoSmithKline PLC Stock Performance Indicators

Estimated Market Risk
  actual daily
 13 %
of total potential
Expected Return
  actual daily
 3 %
of total potential
Risk-Adjusted Return
  actual daily
 7 %
of total potential
Based on monthly moving average GlaxoSmithKline PLC is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GlaxoSmithKline PLC by adding it to a well-diversified portfolio.

About GlaxoSmithKline PLC Performance

To evaluate GlaxoSmithKline PLC Stock as a possible investment, you need to clearly understand its upside, downside potential, and overall future performance outlook. You may be satisfied when GlaxoSmithKline PLC generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare GlaxoSmithKline's stock performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand GlaxoSmithKline PLC stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents GlaxoSmithKline's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2020
Effect of Exchange Rate Changes on Cash(82,000,000) (84,157,895) 
Return on Investment 18.28  23.20 
Return on Average Assets 0.07  0.07 
Return on Average Equity 0.61  0.90 
Return on Invested Capital 0.17  0.19 
Return on Sales 0.19  0.20 
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in the United States and is traded on BATS Exchange. It employs 99437 people.

GlaxoSmithKline PLC Alerts

Equity Alerts and Improvement Suggestions

GlaxoSmithKline PLC has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial commitments
The company has 36.63 B in debt with debt to equity (D/E) ratio of 182.9, demonstrating that the company may be unable to create cash to meet all of its financial commitments. GlaxoSmithKline PLC has a current ratio of 0.8, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.
GLAXOSMITHKLINE P has about 5.12 B in cash with (5.78 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.08.
On 14th of May 2020 GlaxoSmithKline PLC paid $ 0.472 per share dividend to its current shareholders
Latest headline from Mercks Pneumococcal Vaccine Meets Goal in Two Adult Studies - Nasdaq

GlaxoSmithKline PLC Dividends

GlaxoSmithKline PLC Dividends Analysis

Check GlaxoSmithKline PLC dividend payout schedule and payment analysis over time. Analyze past dividends calendar and estimate annual dividend income
Check Dividends  
Please check Risk vs Return Analysis. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page